Biotech RadarJobs updated

COMPANY

Sorrento Therapeutics, Inc.

HQ: San Diego, CA source · sorrentotherapeutics.com ↗

Clinical Phase 3

Also known as Sorrento Therapeutics · 59 sources

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Covid19 COVID-19 Knee Osteoarthritis Knee Pain Chronic Intractable Pain Pain Cancer Light Chain (AL) Amyloidosis Multiple Myeloma Ards Prostate Cancer Prostate Cancer Metastatic Peripheral T Cell Lymphoma Diffuse Large B Cell Lymphoma Biliary Tract Cancer Nasal Extranodal NK T Cell Lymphoma Rheumatoid Arthritis Cancer of Pancreas Sarcoma Hepatic Metastasis Long-term Follow-up Metastatic Pancreatic Carcinoma Mycosis Fungoides Migraine Disorders Peritoneal Carcinomatosis Peritoneal Metastases Colorectal Cancer Gastric Cancer Breast Cancer Pancreas Cancer Carcinoembryonic Antigen Malignant Tumor of Pancreas Metastatic to Liver Relapsed or Refractory Multiple Myeloma Osteo Arthritis Knee Acute Respiratory Distress Syndrome

46Trials (company is sponsor)13NIH grants

Timeline

  1. Trial start Phase 2: Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer source ↗
  2. Trial start Phase 2: Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer source ↗
  3. Trial start Phase 2: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise source ↗
  4. Trial start Phase 1: An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis source ↗
  5. Trial start Phase 1: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors source ↗
  6. Trial start Phase 2: Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents source ↗
  7. Trial start Phase 2: A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies source ↗
  8. Trial start Phase 1: Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors source ↗
  9. Trial start Phase 1/Phase 2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma source ↗
  10. Trial start Phase 1: Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors source ↗
  11. Trial start Phase 1: Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma source ↗
  12. Trial start Phase 1: Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. source ↗
  13. Trial start Phase 1: Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers source ↗
  14. Trial start Phase 1: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors source ↗
  15. Trial start Phase 2: Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress source ↗
  16. Trial start Phase 2: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress source ↗
  17. Trial start Phase 2: Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US) source ↗
  18. Trial start Phase 2: Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis source ↗
  19. Trial start Phase 2/Phase 3: Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases source ↗
  20. Trial start Phase 2: Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection source ↗
  21. Trial start Phase 2: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome source ↗
  22. Trial start Phase 2: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise source ↗
  23. Trial start Phase 2: Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK) source ↗
  24. Trial start —: Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy source ↗
  25. Trial start Phase 2: Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors source ↗

Showing 25 of 46 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 46

RecordTitlePhaseStatusStartPrimary completion
NCT04992247Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromisePhase 2Withdrawn2024-022024-07 (estimated)
NCT05067257Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced CancerPhase 2Suspended2025-092027-06 (estimated)
NCT05361915Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate CancerPhase 2Suspended2025-092028-01 (estimated)
NCT03999658A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesPhase 2Withdrawn2023-032024-01 (estimated)
NCT05692908An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL AmyloidosisPhase 1Withdrawn2023-092024-09 (estimated)
NCT04559412Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid ArthritisPhase 1Unknown status (ClinicalTrials.gov)Mar 15, 20212024-01 (estimated)
NCT05361954Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid TumorsPhase 1Not yet recruiting2023-082026-10 (estimated)
NCT05308225Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Feb 1, 20232025-12 (estimated)
NCT05372783Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and AdolescentsPhase 2Withdrawn2023-042024-06 (estimated)
NCT05364840Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy VolunteersPhase 1CompletedJun 7, 2022Oct 18, 2022 (actual)
NCT04900428Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)Phase 2TerminatedJul 16, 2021Mar 22, 2022 (actual)
NCT05584709Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid TumorsPhase 1Unknown status (ClinicalTrials.gov)2023-032025-08 (estimated)
NCT05060276Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid TumorsPhase 1Withdrawn2022-122024-05 (estimated)
NCT05472649Long-Term Follow-Up of Patients Who Received Gene-Modified Cell TherapyNot listedEnrolling by invitationJun 16, 20212036-12 (estimated)
NCT04440007Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19Phase 2CompletedOct 9, 2020Jul 1, 2021 (actual)
NCT04900519Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid TumorsPhase 1Unknown status (ClinicalTrials.gov)Nov 24, 20212024-12 (estimated)
NCT03818165Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases1TerminatedJul 29, 2019Jan 19, 2020 (actual)
NCT05007418Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple MyelomaPhase 1Unknown status (ClinicalTrials.gov)Oct 1, 20222025-12 (estimated)
NCT04316442Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL AmyloidosisPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Apr 1, 20212024-09 (estimated)
NCT04885972Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee OsteoarthritisPhase 2Unknown status (ClinicalTrials.gov)Nov 15, 20212023-09 (estimated)
NCT04903327Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory DistressPhase 2TerminatedNov 16, 2021Aug 29, 2022 (actual)
NCT04118868Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.Phase 1Unknown status (ClinicalTrials.gov)Aug 31, 2022Jan 29, 2024 (estimated)
NCT04771351Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19Phase 2Withdrawn2021-042021-08 (estimated)
NCT03229798Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)1CompletedJan 17, 2018Mar 28, 2018 (actual)
NCT04905836Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory DistressPhase 2Unknown status (ClinicalTrials.gov)Nov 16, 20212022-12 (estimated)
NCT03682744CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)Phase 1WithdrawnSep 13, 20182020-12 (estimated)
NCT04037241Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver MetastasesPhase 2/Phase 3WithdrawnNov 1, 2021Jan 1, 2022 (estimated)
NCT04809012Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid TumorsPhase 2Withdrawn2021-062024-06 (estimated)
NCT04486001Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19Phase 1CompletedDec 15, 2020Jun 9, 2021 (actual)
NCT03464916Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma PatientsPhase 1CompletedOct 15, 2018Aug 23, 2020 (actual)
NCT04734860Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 SymptomsPhase 2Withdrawn2021-042021-09 (estimated)
NCT04738175Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19Phase 1/Phase 2Withdrawn2021-042021-11 (estimated)
NCT04906694Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)Phase 2CompletedNov 16, 2021Jan 13, 2022 (actual)
NCT05074394Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 InfectionPhase 2Withdrawn2021-112022-11 (estimated)
NCT04044742A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee3Withdrawn2020-122023-03 (estimated)
NCT04572776Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain3Withdrawn2020-122023-03 (estimated)
NCT04386980Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is DelayedPhase 3Withdrawn2021-042022-06 (estimated)
NCT04528667Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19Phase 2CompletedJan 6, 2021Aug 23, 2021 (actual)
NCT04909879Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress SyndromePhase 2Withdrawn2021-092022-02 (estimated)
NCT04728698Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory DistressPhase 2Withdrawn2021-032021-09 (estimated)
NCT04909892Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromisePhase 2Withdrawn2021-082022-01 (estimated)
NCT03542838Study of Resiniferatoxin for Knee Pain in Moderate to Severe OsteoarthritisPhase 1CompletedJul 12, 2018Apr 13, 2020 (actual)
NCT04584697Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19Phase 1/Phase 2Withdrawn2020-122021-04 (estimated)
NCT04454398Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19Phase 1Withdrawn2020-092021-01 (estimated)
NCT03226574Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer PainPhase 1CompletedSep 1, 2017Mar 18, 2020 (actual)
NCT02064829Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast CancerNot phased (device or behavioral study)Completed2014-032015-02 (actual)

NIH awards 13

Annual award amounts. Total $9.4M.

Feedback